BioCryst’s immune disorder drug succeeds in mid-stage trialReuters(Reuters) – BioCryst Pharmaceuticals Inc said its experimental drug for treating a rare immune disorder was effective in reducing the attacks of the disease in a mid-stage trial. The drug, BCX4161, was compared with a placebo and was being tested in patients …BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 …MarketWatchall 2 news articles …Read Full Story
BioCryst's immune disorder drug succeeds in mid-stage trial - Reuters
Real Estate of Cebu
